CRISPR-Cas12b/C2c1 Tested in Targeted Mutagenesis of a DicotMay 20, 2020
Cas12b/C2c1 has been identified as class 2 endonuclease that can be used for targeted genome editing in rice and mammals. To elucidate its potential applications in dicots, CRISPR-Cas12b system was tested in Arabidopsis thaliana.
Researchers from Hebei University of Science and Technology in China selected BvCas12b and BhCas12b v4 for analysis. Both endonucleases were successfully applied to cause mutations, conduct multiplex genome editing, and create large deletions at multiple loci. There were no significant mutations detected at potential off-target locations. The team also reported the results of their analysis of the insertion/deletion frequencies and patterns of mutants generated using targeted gene mutagenesis which showed the potential use of CRISPR-Cas12b systems for genome editing in Arabidopsis.
Read the abstract in the Journal of Integrative Plant Biology.
You might also like:
- Scientists Develop New CRISPR Platform for DNA Targeting
- Researcher Establishes CRISPR-Cas12b System for Plant Genome Engineering
- Pocket K No. 54: Plant Breeding Innovation: CRISPR-Cas9
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
News from Around the World
- ISAAA Monitors Progress of Research on COVID-19
- Kenyan Researchers Seek Approval to Introduce Disease-Resistant Cassava
- ARS Scientists Identify Genes Associated with Postharvest Deterioration of Fresh-Cut Lettuce
- USDA Finalizes SECURE, Eases Up Biotech Regulations
- Scientists Solve 20-Year Old Wheat Genetics Puzzle
- South Australia Moves Closer to Planting GM Crops
- EFSA Releases Scientific Opinion on Oilseed Rape MS11
- Plant Viruses Found to Potentially Treat Diabetes, Arthritis
- CRISPR-Cas12b/C2c1 Tested in Targeted Mutagenesis of a Dicot
- Medicago Announces Positive Results of Trials for its COVID-19 Vaccine Candidate
Read the latest:
- Biotech Updates (February 21, 2024)
- Gene Editing Supplement (February 14, 2024)
- Gene Drive Supplement (February 22, 2023)
Subscribe to BU: